StockIQpro
NASDAQ:OBIO

Orchestra BioMed Holdings, Inc.

Track all markets on TradingView
Track all markets on TradingView

Orchestra BioMed Holdings, Inc.'s revenue grew 1169.2% in fiscal 2025 to $33.5M while operating margin rose to −154.7%, its highest in 4 years. Free cash flow was −$49.5M, −147.7% of revenue, and the diluted share count rose 29.7%.Summary generated from Orchestra BioMed Holdings, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$33.5M
Revenue growth+1169.2%
Revenue, 5-yr CAGRn/a
Gross margin99.4%
Operating margin−154.7%
Net margin−157.4%
ROIC−137.4%
Return on equity−121.8%
Debt / equity0.28
Free cash flow−$49.5M
FCF margin−147.7%
Share count change+29.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a43333
Operating income−0−33−52−64−52
Net income−0−34−49−61−53
Free cash flown/a−30−46−51−49

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus